It is reported that HO-1 has a certain inhibitory effect on prostate cancer, which may be attributed to its regulatory effect on proangiogenic factors by significantly downregulating VEGF-A, VEGF-C, and MMP-9 expression level [15] and inhibiting the NF-κB signaling pathway [16]. Here, HMOX1 is linked to prostate carcinoma.